Brief: Briacell Therapeutics Says Evaluating Bria-BRES In Phase 1/2A Study For Breast Cancer
10/09/2024 14:15
Sept 10 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR
BRIA-PROS+™ FOR PROSTATE CANCER
* BRIACELL THERAPEUTICS CORP - EVALUATING BRIA-BRES™ IN
PHASE 1/2A
STUDY FOR BREAST CANCER
Source text for Eikon: ID:nGNX5GvcSS
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study